Vi
Not verified

Vividion Therapeutics, Inc.

What we write about

BiotechnologyHealthMedicine - variousOncologyPharmaceuticals
09/10/2025
Oncology
Health
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
Industria
Vividion Announces Publication in Science of Preclinical Data on Covalent Inhibitors of RAS-PI3K that Block Tumor Growth
1.00
13/08/2025
Biotechnology
Sanità
Health
Pharmaceuticals
Oncology
Labour market
Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer
1.00
04/06/2025
Industria
Oncology
Health
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor
1.00
03/04/2025
Industria
Biotechnology
Health
Pharmaceuticals
Medicine - various
Oncology
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
1.00
22/01/2025
Labour market
Biotechnology
Pharmaceuticals
Health
Oncology
Vividion Therapeutics Announces Promotion of Jean Bemis to Chief Operating Officer
1.00
08/01/2025
stock market
Industria
Tecnica
Scienza
Biotechnology
Software
Health
Pharmaceuticals
Oncology
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
1.00
08/10/2024
Labour market
Scienza
Biotechnology
Pharmaceuticals
Oncology
Health
Medicine - various
Vividion Therapeutics Appoints Frank Poschen to Board of Directors
1.00
23/07/2024
Multimedia
Scienza
Biotechnology
Pharmaceuticals
Oncology
Health
Medicine - various
Industria
Vividion Therapeutics to Expand with New Global Research and Development Center
1.00
25/04/2024
Accessories
Windows / Shopping
Health
Fitness / Wellness
Management
Medicine - various
Scienza
Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN)
1.00

Contact details

Social Media

Followers
0
Compatibility
0